A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

This study is testing a combination of two experimental treatments — pasritamig (JNJ-78278343) and JNJ-86974680 — in men with metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone reduction therapy). **You may be eligible if...** - You have confirmed prostate adenocarcinoma that has spread to bone or lymph nodes but not to internal organs (visceral metastases) - Your cancer has stopped responding to standard hormone therapy (castration-resistant) - You are currently on androgen deprivation therapy (medical or surgical castration) and will continue it - Your PSA level is 2 ng/mL or higher at screening - You are in good physical condition (ECOG 0 or 1) **You may NOT be eligible if...** - You have unresolved treatment side effects from prior cancer therapy (above grade 1) - You have a known allergy to the study drugs or their components - You have cancer that has spread to internal organs (visceral metastases) - You have primary small cell, carcinoid, or pure neuroendocrine prostate cancer Talk to your doctor to see if this trial is right for you.